Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes

Open access

Abstract

BACKGROUND: Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The safety and pharmacokinetics of oral semaglutide were investigated in two randomised, double-blind, placebo-controlled trials. METHODS: In a single-dose, first-in-human trial, 135 healthy males received oral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC) or placebo with SNAC. In a 10-week, once-daily, multiple-dose trial, 84 healthy males received 20 or 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC, and 23 males with type 2 diabetes (T2D) received 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC. RESULTS: Oral semaglutide was safe and well-tolerated in both trials. The majority of adverse events (AEs) were mild, with the most common AEs being gastrointestinal disorders. In the single-dose trial, semaglutide exposure was highest when co-formulated with 300 mg SNAC. In the multiple-dose trial, semaglutide exposure was approximately twofold higher with 40 versus 20 mg oral semaglutide in healthy males, in accordance with dose proportionality, and was similar between healthy males and males with T2D. The half-life of semaglutide was approximately 1 week in all groups. CONCLUSION: The safety profile of oral semaglutide was as expected for the GLP-1 receptor agonist drug class. Oral semaglutide co-formulated with 300 mg SNAC was chosen for further clinical development. The pharmacokinetic results supported that oral semaglutide is suitable for once-daily dosing. CLINICALTRIALS. GOV IDENTIFIERS: NCT01037582, NCT01686945.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-018-0728-4

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC · From the PDF
Fig. 2 Arithmetic mean semaglutide plasma concentration-time profiles after a single dose of oral semaglutide with varying amounts of SNAC in healthy male subjects (single-dose trial). Semaglutide plasma concentrations are expressed in percentage of the maximum mean concentration for a 5 mg oral semaglutide with 300 mg SNAC, or b 10 mg oral semaglutide with 300 mg SNAC (see Sect. 2.4 for further details). For subjects with no measurable semaglutide plasma concentration, concentrations were set to 0. SNAC sodium N -(8-[2hydroxybenzoyl] amino) caprylate Modified from Buckley et al. [5]
Fig. 2 Arithmetic mean semaglutide plasma concentration-time profiles after a single dose of oral semaglutide with varying amounts of SNAC in healthy male subjects (single-dose trial). Semaglutide plasma concentrations are expressed in percentage of the maximum mean concentration for a 5 mg oral semaglutide with 300 mg SNAC, or b 10 mg oral semaglutide with 300 mg SNAC (see Sect. 2.4 for further details). For subjects with no measurable semaglutide plasma concentration, concentrations were set to 0. SNAC sodium N -(8-[2hydroxybenzoyl] amino) caprylate Modified from Buckley et al. [5]CC-BY-NC · From the PDF
Fig. 3 Arithmetic mean semaglutide plasma concentration-time profiles after ascending single doses of oral semaglutide with 300 mg SNAC in healthy male subjects (single-dose trial). Semaglutide plasma concentrations are expressed in percentage of the maximum mean concentration for 10 mg oral semaglutide with 300 mg SNAC (see Sect. 2.4 for further details). For subjects with no measurable semaglutide plasma concentration, concentrations were set to 0. SNAC sodium N -(8-[2-hydroxybenzoyl] amino) caprylate
Fig. 3 Arithmetic mean semaglutide plasma concentration-time profiles after ascending single doses of oral semaglutide with 300 mg SNAC in healthy male subjects (single-dose trial). Semaglutide plasma concentrations are expressed in percentage of the maximum mean concentration for 10 mg oral semaglutide with 300 mg SNAC (see Sect. 2.4 for further details). For subjects with no measurable semaglutide plasma concentration, concentrations were set to 0. SNAC sodium N -(8-[2-hydroxybenzoyl] amino) caprylateCC-BY-NC · From the PDF
Fig. 4 Geometric mean semaglutide plasma concentration-time profiles at steady state (multiple-dose trial). Profiles represent geometric means of the last 3 days of once-daily oral semaglutide treatment for 10 weeks. T2D type 2 diabetes
Fig. 4 Geometric mean semaglutide plasma concentration-time profiles at steady state (multiple-dose trial). Profiles represent geometric means of the last 3 days of once-daily oral semaglutide treatment for 10 weeks. T2D type 2 diabetesCC-BY-NC · From the PDF
Fig. 5 Comparison of a AUC 0-24 h,semaglutide,SS and b C max,semaglutide,SS between 20 and 40 mg doses of oral semaglutide in healthy males and between healthy males and males with T2D receiving 40 mg oral semaglutide (multiple-dose trial). Bars are estimated means and 95% CIs. Treatment comparisons show estimated treatment ratios
Fig. 5 Comparison of a AUC 0-24 h,semaglutide,SS and b C max,semaglutide,SS between 20 and 40 mg doses of oral semaglutide in healthy males and between healthy males and males with T2D receiving 40 mg oral semaglutide (multiple-dose trial). Bars are estimated means and 95% CIs. Treatment comparisons show estimated treatment ratiosCC-BY-NC · From the PDF
[95% CI] and p value. AUC 0-24 h,semaglutide,SS area under the semaglutide plasma concentration-time curve from 0 to 24 h at steady state, Cmax,semaglutide,SS maximum plasma semaglutide concentration at steady state, T2D type 2 diabetes, CI confidence interval
[95% CI] and p value. AUC 0-24 h,semaglutide,SS area under the semaglutide plasma concentration-time curve from 0 to 24 h at steady state, Cmax,semaglutide,SS maximum plasma semaglutide concentration at steady state, T2D type 2 diabetes, CI confidence intervalCC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 1

  1. Bækdal TA, Borregaard J, Donsmark M, Breitschaft A, Søndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide [abstract]. Diabetes. 2017;66(Suppl 1):A315.

Cited by

See all 205

Metadata

Authors
Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A.
Affiliations
Novo Nordisk (Denmark) (DK)
Corresponding author
Bækdal, Tine A.
Venue
Clinical Pharmacokinetics
Published
2018-12-18
Volume
58
Issue
6
Pages
781-791
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2903677519
Cited by
190
References
12
Citations by year
2026: 24 · 2025: 31 · 2024: 26 · 2023: 18 · 2022: 24 · 2021: 26 · 2020: 28 · 2019: 13
FWCI
13.53
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0 (tdm)
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, semaglutide, GLP-1 receptor agonists, SNAC, absorption enhancers, pharmacokinetics, safety, type 2 diabetes, dose proportionality, half-life, gastrointestinal adverse effects
MeSH terms
Semaglutide, Administration, Oral, Adolescent, Adult, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Male, Metabolic Clearance Rate, Middle Aged, Area Under Curve, Glucagon-Like Peptide 1, Young Adult, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s40262-018-0728-4
The paper
Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A. (2019). Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-018-0728-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.